Journal ArticleOPEN ACCESS

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

  • Ning Y
  • Maher V
  • Beaver J
  • et al.
The Oncologist (2018) 23(2) 139-142
DOI: 10.1634/theoncologist.2017-0415
4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies.

Cite

CITATION STYLE

APA

Ning, Y.-M., Maher, V. E., Beaver, J. A., Goldberg, K. B., Blumenthal, G. M., & Pazdur, R. (2018). Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma. The Oncologist, 23(2), 139–142. https://doi.org/10.1634/theoncologist.2017-0415

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free